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ket access as well as potentially leading to significant price reductions. What do
these changes mean for the industry? What are the main challenges and opportu-
nities for companies and how can they best adapt? Many questions remain to be
determined. Yet AMNOG sets the scene for a new Market access process in Ger-
many, for which challenges can be foreseen. The industry will need to acquire new
skills to interact with national Market access stakeholders, develop internal effi-
cient processes to compile Benefit Dossiers, adapt the European launch sequence
as well as investigate new Market access strategies, for example targeting sub-
target population groups to demonstrate higher additional benefit or leveraging
Phase IV data. CONCLUSIONS: Industry needs to prepare itself for developing their
launch and commercial strategies in Germany as Germany is a key market from
revenue, price referencing and credibility perspective.
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OBJECTIVES: Spending on prescription drugs in key OECD countries has increased
by 50% or more in the last ten years, raising questions about overall system sus-
tainability. The study analyses possible reasons for differences in prices and vol-
umes consumed across key OECD countries, taking into account national differ-
ences in pharmaceutical policy and regulatory mechanisms.METHODS: Panel data
modelling is used to investigate the effect of pharmaceutical pricing and reim-
bursement regulations, drug promotion, drug use, and competition on price levels.
Data are from IMS Health and the US Federal Supply Schedule and include top-50
selling on patent and generic prescription drugs used in the study countries. Reg-
ulatory variables are included as dummy variables in the model. RESULTS: Prelim-
inary results suggest that: a) cross-country price comparisons are only meaningful
if the right prices are compared in each case. Here, we demonstrate how significant
price differences are when ex-factory prices are compared and how these differ-
ences narrow down significantly when public prices are compared across countries;
b) It seems that price differences of originator brands between the US and Europe
have been exaggerated; generic prices are very often significantly lower in the US
than in other countries; c) Cross-country public price differences and cross-country
ex-factory price differences are not the same across the study countries; d) Off-
patent originator brands account for a significant proportion of the price variation
between US and the other study countries; e) Pricing regulation accounts for a
considerable proportion of the variation in prices across the study countries; and f)
Distribution and taxation can contribute significantly to the total cost of prescrip-
tion medicines that health insurers pay. CONCLUSIONS: Price differences are sig-
nificant when ex-factory prices are compared but are significantly reduced when
public prices are compared across countries. Regulation, distribution, and taxes are
key contributors to the total cost of medicines paid by insurers.
PODIUM SESSION II:
MIXED TREATMENT COMPARISONS MATURE, IN ABSENCE OF SUFFICIENT
HEAD-TO-HEAD COMPARISONS
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OBJECTIVES: Bayesian network meta-analyses incorporate prior distributions
(“priors”) that are updated with new evidence to generate posterior distributions.
The use of uninformative (vague) priors minimizes potential biases and promotes
transparency. Guideline developers have recommended values for uninformative
priors for binary outcomes. For continuous outcomes, the choice of priors is scale-
dependent. In networks with heterogeneity and few studies, a more informed prior
for estimation of between-studies standard deviation () is justifiable, yet may
impose subjectivity. Using a network meta-analysis of seven studies estimating
the efficacy of three renal transplant immunosuppressants (tacrolimus, cyclospo-
rine and belatacept), we estimated the impact of varying priors for  to the relative
effect sizes. METHODS: We established a clinically-plausible range for an uninfor-
mative prior distribution of . We then derived estimates for the indirect compar-
ison of belatacept and tacrolimus expressed as true mean difference (TMD) in renal
function, expressed as glomerular filtration rate (GFR; mL/min/1.73m2); 95% cred-
ible intervals (CrI); and model fit (residual deviance and deviance information cri-
terion). We conducted sensitivity analyses using more informed priors: half the
uninformative range; a data-driven approach; half the data-driven range; and, as
an extreme, a fixed-effect model (  0). RESULTS: Using the uninformative uni-
form prior, U(0,20), the estimated TMD in GFR was 9.84 higher for belatacept than
tacrolimus. This had the best model fit and the widest 95% CrI (1.97, 20.51). As the
upper bound of the prior distribution was restricted, the 95% CrIs narrowed yet the
model fit degraded. The point estimate was stable. The narrowest informed prior
was U(0,3) (TMD 9.84; 95% CrI 4.89, 15.90).CONCLUSIONS: In this analysis, the point
estimates for TMD in GFR consistently favored belatacept, yet the CrIs and model fit
were affected by the choice of prior for . Given the subjectivity in selecting priors
for continuous outcomes, transparent reporting is essential.
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OBJECTIVES: Each of the tumour necrosis factor alpha antagonists (anti-TNF-)
available to treat rheumatoid arthritis have demonstrated considerable efficacy in
placebo controlled trials, but few head-to-head comparisons exist to date. This
work estimates the relative efficacy among licensed anti-TNFs and highlights the
advantages of continuous outcome measures in mixed treatment comparison
models. METHODS: Relative efficacy was estimated using Bayesian mixed treat-
ment comparison (MTC) models. Three different outcome measures were used;
Risk ratios of achieving an ACR20 and ACR50 response (binomial outcomes) and the
percentage improvement in HAQ score (continuous outcome). Five anti-TNF- an-
tagonists were included in the analysis; adalimumab, infliximab, etanercept, goli-
mumab and certolizumab. RESULTS: All anti-TNF agents show a significant im-
provement over placebo across all outcome measures. The HAQ model outcomes
provide evidence that all anti-TNF agents show improvement over infliximab. This
effect is not found with the ACR outcomes for adalimumab and golimumab. Fur-
thermore, the HAQ model indicates a superiority of etanercept over adalimumab.
The evidence of certolizumab pegol providing improvement over golimumab,
which can be found in the ACR outcomes, is not apparent in the HAQ outcomes.
CONCLUSIONS: Continuous outcome measures make better use of the complete
data than binomial measures and are therefore more sensitive to change. The
results suggest that it may be the case, in mixed treatment comparison models,
where the essence lies in detecting differences, a continuous outcome measure is
more appropriate. Its enhanced sensitivity to change increases the power of the
model to detect differences among treatments. The HAQ multiplier provides one
such measure, but others exist.
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OBJECTIVES: Model fit in Bayesian mixed treatment comparisons (MTC) is often
assessed by the deviance information criterion (DIC). In some cases DIC is not
conclusive. Our aim was to compare DIC with an alternative approach: formal
Bayesian model comparison by estimating the posterior distribution over the
model space. METHODS: DIC is a criterion which combines posterior mean of the
deviance and deviance of posterior means. Models with lower DIC should be pre-
ferred, however if the difference in DICs is small the decision should not be based
solely on DIC. Marginal data density (MDD) expresses probability of observing given
dataset. Decision rule based on Bayesian model comparison is that the model with
highest a posteriori probability should be chosen. Data from few systematic reviews
indexed in Pubmed were extracted in order to find MTC datasets for which DICs for
fixed (FEM) and random effects models (REM) are very similar. Two continuous
variables datasets were chosen. Posterior distributions and DICs were estimated in
WinBugs. The Newton-Raftery estimator of MDD was implemented in Java, to-
gether with the Gibbs sampler. In both cases, in which DIC was not conclusive, two
a priori structures over the model space were assumed: an uniform distribution and
one penalizing the models for the excessive number of parameters. RESULTS: In
the first dataset difference in DICs was 1.3 (in favor REM), in the second dataset this
difference was 2,0 (in favor FEM). In both cases REM turned out to have a higher
value of MDD. Although a priori odds ratio was around 100:1 for FEM, the posterior
distribution was in every case close to have probability of one (0.9999) for the REM.
CONCLUSIONS: Decision about model selection should include tools of formal
model comparison, as conclusions coming from it are always interpretable and
coherent within Bayesian inference.
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OBJECTIVES: Cost-effectiveness analysis must use all relevant sources of evi-
dence to inform reimbursement decisions. Mixed treatment comparisons (MTC)
extends the traditional pair-wise meta-analytic framework to facilitate the syn-
thesis of information on more than two interventions. While most MTCs use
aggregate data (AD), a proportion of the evidence base might be available at the
individual level (IPD). This paper develops novel statistical models aimed to
fully exploit the existing data, regardless of the format (i.e. AD or IPD).
METHODS: We develop a series of novel Bayesian statistical MTC models to allow
for the simultaneous synthesis of IPD and AD, while considering study and indi-
vidual level covariates, and use these to inform a decision model. RESULTS: The
effectiveness of home safety education and the provision of functioning smoke
alarms (binary outcome – Yes/No) for the prevention of childhood injuries in the
household was used as a motivating example. Case study included 20 trials (11 AD,
9 IPD), summing up to 11,500 participants. Seven strategies were defined and a
network of evidence was constructed. Irrespective of the evidence format used, all
models which did not consider information on covariate(s) showed equivalent
results, i.e. more intensive interventions (providing education, equipment (with
fitting) and home inspection) were more effective (OR vs usual care of 4.5 (95%
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